바이오마린 (BMRN)

전일 마감가:

$83.80

열려 있는:

$84.8

하루 거래량:

1.62M

시가총액:

$15.65B

수익:

$2.47B

순이익/손실:

$205.46M

주가수익비율:

107.25

EPS:

0.7687

순현금흐름:

$163.21M

1주 성능:

+1.89%

1개월 성능:

-5.00%

6개월 성능:

+3.58%

1년 성능:

-11.90%

1일 변동 폭

$82.32

$84.80

52주 변동 폭

$76.02

$99.56

바이오마린 Stock (BMRN) Company Profile

명칭

Biomarin Pharmaceutical Inc.

부문

Healthcare (1213)

산업

Biotechnology (699)

전화

415-506-6700

주소

770 Lindaro Street, San Rafael, CA

직원

2,581

트위터

다음 수익 날짜

2024-05-21

최신 SEC 제출 서류

BMRN's Discussions on Twitter

바이오마린 Stock (BMRN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-11-15	개시	Wells Fargo	Overweight
2023-10-23	업그레이드	Bernstein	Underperform → Mkt Perform
2023-09-28	개시	Raymond James	Mkt Perform
2023-09-18	개시	UBS	Buy
2023-07-27	개시	Scotiabank	Sector Perform
2023-07-05	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-06-14	재개	Credit Suisse	Outperform
2023-03-21	개시	Bernstein	Underperform
2023-02-22	다운그레이드	Oppenheimer	Outperform → Perform
2023-02-21	개시	Citigroup	Neutral
2023-01-30	개시	BMO Capital Markets	Market Perform
2023-01-18	개시	Canaccord Genuity	Hold
2022-10-31	업그레이드	Oppenheimer	Perform → Outperform
2022-07-13	개시	Cantor Fitzgerald	Overweight
2022-06-13	재개	Wedbush	Neutral
2022-04-25	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	업그레이드	William Blair	Mkt Perform → Outperform
2021-10-07	재개	Jefferies	Buy
2021-09-09	업그레이드	Stifel	Hold → Buy
2021-06-04	재개	Robert W. Baird	Outperform
2021-04-26	재개	Credit Suisse	Outperform
2021-03-04	재개	Guggenheim	Buy
2021-03-01	업그레이드	Evercore ISI	In-line → Outperform
2020-08-20	다운그레이드	Citigroup	Buy → Neutral
2020-08-20	다운그레이드	William Blair	Outperform → Mkt Perform
2020-08-19	다운그레이드	Evercore ISI	Outperform → In-line
2020-08-19	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	다운그레이드	Stifel	Buy → Hold
2020-07-08	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	재확인	Citigroup	Buy
2020-01-28	개시	BMO Capital Markets	Market Perform
2020-01-27	개시	BMO Capital Markets	Market Perform
2020-01-24	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	업그레이드	Barclays	Equal Weight → Overweight
2019-11-12	개시	SunTrust	Buy
2019-10-17	재개	BofA/Merrill	Buy
2019-05-23	재개	Citigroup	Buy
2019-04-09	재개	Raymond James	Outperform
2019-01-02	다운그레이드	Raymond James	Outperform → Mkt Perform
2018-12-14	개시	Wolfe Research	Outperform
2018-10-01	개시	Cantor Fitzgerald	Overweight
2018-08-07	재확인	Stifel	Buy
2018-08-03	재확인	Stifel	Buy

모두보기

바이오마린 주식(BMRN)의 최신 뉴스

4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The Motley Fool

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)

Benzinga

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

Zacks Investment Research

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates

Zacks Investment Research

Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?

Zacks Investment Research

바이오마린 (BMRN) 재무 분석

바이오마린 (BMRN) 매출 2024

바이오마린 (BMRN) 순이익 2024

바이오마린 (BMRN) 현금흐름 2024

바이오마린 (BMRN) 주당 순이익 2024